Japan Medical Marijuana Market Size, Share, By Product Type (Flower, Oil & Tinctures), By Application (Pain Disorders, Cancer, and Others), Japan Medical Marijuana Market Insights, Application Trend, Forecasts to 2035.
Industry: Healthcare
Japan Medical Marijuana Market Insights Forecasts to 2035
- Japan Medical Marijuana Market Size 2024: USD 29.5 million
- Japan Medical Marijuana Market Size 2035: USD 2604.3 million
- Japan Medical Marijuana Market CAGR 2024: 50.28%
- Japan Medical Marijuana Market Segments: Product Type and Application
Get more details on this report -
The Japan medical marijuana market refers to the regulated industry for cannabis-based medicines used to treat specific medical conditions in Japan under strict government laws and pharmaceutical approvals.
Elision Japan launched a CBD tincture product (CBD Tincture Night Time) tailored for wellness use in the Japanese market, expanding functional cannabinoid offerings.
Government Policy Decisions and Cabinet Approval – In 2023, Japan’s Cabinet Office formally adopted policy measures that enhance medical cannabis usage conditions as part of their comprehensive reform initiatives, which also include plans for social insurance and clinical system integration.
The future of Japan's medical marijuana market shows strong growth potential because of regulatory changes and cannabis-based medicine approvals, and increased need for epilepsy treatment, domestic cultivation license grants and rising medical studies about cannabinoid treatments.
Market Dynamics of the Japan Medical Marijuana Market:
The Japan medical marijuana market is driven by the recent amendments to the Cannabis Control Law, rising acceptance of cannabinoid-based medicines, increasing epilepsy and chronic pain cases, pharmaceutical R&D investments, and growing awareness about regulated medical cannabis therapies under strict government supervision.
The Japan medical marijuana market is restrained by the strict THC regulations, limited product approvals, social stigma, complex licensing procedures, and tight government monitoring of cultivation, distribution, and prescription practices.
The future of the Japan medical marijuana market is bright and promising, with the expansion of pharmaceutical cannabis approvals, controlled domestic cultivation, stronger clinical research, and gradual integration into Japan’s regulated healthcare system.
Japan Medical Marijuana Market Report Coverage
| Report Coverage | Details |
|---|---|
| Base Year: | 2024 |
| Market Size in 2024: | USD 29.5 Million |
| Forecast Period: | 2025-2035 |
| Forecast Period CAGR 2025-2035 : | 50.28% |
| 2035 Value Projection: | USD 2604.3 Million |
| Historical Data for: | 2020-2023 |
| No. of Pages: | 210 |
| Tables, Charts & Figures: | 89 |
| Segments covered: | By Product Type, By Application |
| Companies covered:: | Jazz Pharmaceuticals (GW Pharmaceuticals), Tilray Brands, Canopy Growth Corporation, Aurora Cannabis, Curaleaf Holdings, AstraSana Japan, GSI Creos Corporation, Shimadzu Corporation, and Others. |
| Pitfalls & Challenges: | COVID-19 Impact, Challenges, Future, Growth, & Analysis |
Get more details on this report -
Market Segmentation
The Japan medical marijuana market share is classified into product type and application.
By Product Type:
The Japan medical marijuana market is divided by product type into flower, oil & tinctures. Among these, the oil & tinctures segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Due to strict THC regulations, precise dosing, pharmaceutical preference, and easier regulatory approval, compared to raw cannabis flower products.
By Application:
The Japan medical marijuana market is divided by application into pain disorders, cancer, and others. Among these, the pain disorders segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Due to increasing chronic pain cases, demand for alternative therapies, and growing clinical evidence supporting cannabinoid-based pain management treatments.
Competitive Analysis:
The report offers the appropriate analysis of the key organisations/companies involved within the Japan medical marijuana market, along with a comparative evaluation primarily based on their Product Type offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes Product Type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Key Companies in Japan Medical Marijuana Market:
- Jazz Pharmaceuticals (GW Pharmaceuticals)
- Tilray Brands
- Canopy Growth Corporation
- Aurora Cannabis
- Curaleaf Holdings
- AstraSana Japan
- GSI Creos Corporation
- Shimadzu Corporation
- Others
Key Target Audience
- Market Players
- Investors
- Applications
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the Japan medical marijuana market based on the below-mentioned segments:
Japan Medical Marijuana Market, By Product Type
- Flower
- Oil & Tinctures
- Others
Japan Medical Marijuana Market, By Application
- Pain Disorders
- Cancer
- Others
Frequently Asked Questions (FAQ)
-
What is the Japan medical marijuana market size?Japan medical marijuana market is expected to grow from USD 29.5 million in 2024 to USD 2604.3 million by 2035, growing at a CAGR of 50.28% during the forecast period 2025-2035.
-
What are the key growth drivers of the market?Market growth is driven by the recent amendments to the Cannabis Control Law, rising acceptance of cannabinoid-based medicines, increasing epilepsy and chronic pain cases, pharmaceutical R&D investments, and growing awareness about regulated medical cannabis therapies under strict government supervision.
-
What factors restrain the Japan medical marijuana market?Constraints include the strict THC regulations, limited product approvals, social stigma, complex licensing procedures, and tight government monitoring of cultivation, distribution, and prescription practices.
-
How is the market segmented by product type?The market is segmented into flower, oil & tinctures.
-
Who are the key players in the Japan medical marijuana market?Key companies include Jazz Pharmaceuticals (GW Pharmaceuticals), Tilray Brands, Canopy Growth Corporation, Aurora Cannabis, Curaleaf Holdings, AstraSana Japan, GSI Creos Corporation, Shimadzu Corporation, and Others.
-
Who are the target audiences for this market report?The report targets market players, investors, Applications, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).
Need help to buy this report?